Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study

Ito, Yasuo; Mitsufuji, Takashi; Okada, Mariko; Fujita, Shugo; Yokoyama, Ryu; Kawasaki, Hitoshi; Yamamoto, Toshiyuki

doi:10.2169/internalmedicine.1471-22

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, for such severe patients, the new CGRPrelated drugs can perform therapeutic effects. 80,[86][87][88][89][90][91] Further data accumulation is needed.…”

Section: Importance Of Early Medical Consultationmentioning

confidence: 99%

Headache Education by E-Learning Through Social Networking Services (Social Media)

Katsuki,

Nanri,

Miyakoshi

et al. 2023

JHL

View full text Add to dashboard Cite

Introduction Headache is a common public health problem, but its burden could be avoided by raising headache awareness and the appropriate use of acute medication and prophylactic medication. Few reports on raising headache awareness in the general public have been reported, and there are no reports on headache awareness campaigns through social networking services (SNS), or social media, in Japan. We prospectively performed a headache awareness campaign from March 2022 through 2 SNS, targeting nurse and wind instrumental musicians, because they are with high headache prevalence. Methods Through the 2 SNS, the article and video were distributed, respectively. The article and video described the 6 important topics for the general public about headaches, which were described in the Clinical Practice Guideline for Headache Disorders 2021. Just after reading or watching them as e-learning, we performed online questionnaire sheets to investigate the awareness of the 6 topics through the 2 SNS. The awareness of the 6 topics before and after the campaign was evaluated. Results In the SNS nurse-senka, we obtained 1191 responses. Women comprised 94.4%, and the median (range) age was 45 (20 to 71) years old. Headache sufferers were 63.8%, but only 35.1% had consulted doctors. In the SNS Creatone, we got the response from 134 professional musicians, with 77.3% of women. The largest number of respondents were in their 20s (range 18–60 years old). Headache sufferers were 87.9%. Of them, 36.4% had consulted doctors, 24.2% were medication-overuse headache. The ratios of individuals who were aware of the 6 topics significantly increased from 15.2%-47.0% to 80.4–98.7% after the online questionnaire in both SNS (p < 0.001, all). Conclusion E-learning and online survey via SNS can improve headache awareness.

show abstract

“…Also, for such severe patients, the new CGRPrelated drugs can perform therapeutic effects. 80,[86][87][88][89][90][91] Further data accumulation is needed.…”

Section: Importance Of Early Medical Consultationmentioning

confidence: 99%

Headache Education by E-Learning Through Social Networking Services (Social Media)

Katsuki,

Nanri,

Miyakoshi

et al. 2023

JHL

View full text Add to dashboard Cite

show abstract

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study

Ohtani,

Watanabe,

Ihara

et al. 2023

BMC Neurol

View full text Add to dashboard Cite

Background There have been very few real-world studies reported in the literature solely focusing on fremanezumab in Asia. This study aimed to evaluate the efficacy and safety of fremanezumab in a real-world setting in Japan. Method This single-centered, observational, retrospective study examined patients with migraines who received four doses of fremanezumab between December 2021 and August 2022 at Keio University Hospital. We assessed the changes in monthly migraine days, responder rates, and migraine-associated symptoms, as well as injection site reactions and adverse events. Result Twenty-nine patients were enrolled, wherein 79.3% were women. Compared with those at baseline, the monthly migraine days decreased by 5.9 days at 4 months. The 50% responder rate was 55.2% at 4 months. A total of 57.9%, 47.8%, and 65.0% of patients showed improvement in the severity of photophobia, phonophobia, and nausea/vomiting, respectively. Moreover, injection site reactions were the most common adverse events (55.2%). Conclusion Fremanezumab is effective and safe for migraine prevention in Japan. Fremanezumab also improved migraine-associated symptoms in half of the patients.

show abstract

Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization

Tanei,

Fuse,

Maesawa

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Abrupt discontinuation of overused medications is the gold standard treatment for medication overuse headache (MOH), but discontinuation is difficult to maintain. In this study, the aim was to evaluate the real-world clinical results of anti-calcitonin gene-related peptide monoclonal antibody (CGRP-mAb) treatment for MOH of migraine without abrupt drug discontinuation and no hospitalization. Methods Patients with MOH of migraine receiving naïve CGRP-mAb treatment without abrupt drug discontinuation were enrolled. Data were collected before starting CGRP-mAb injections (baseline) and after each injection. The primary endpoint was evaluated after the third injection. The following items were compared between baseline and after each injection: monthly headache days (MHD), monthly migraine days (MMD), monthly acute medication use (AMU) days, monthly total amount of AMU tablets, headache impact test-6 (HIT-6), and the migraine-specific quality of life questionnaire (MSQ). Achieving reduction rates ≥ 50% in the frequency of each headache and migraine (MHD and MMD, respectively) was defined as a good response. Achieving reduction rates of both AMU days and tablets ≥ 50% was defined as effective in reducing AMU. Results This study included 33 patients with MOH of migraine. After the third CGRP-mAb injection, MHD and MMD were significantly decreased from median 30.0 [interquartile range (IQR), 28.0–30.0] days to 9.5 [IQR, 5.5–13.3] days, and 10.0 [IQR, 6.0–15.0] days to 1.5 [IQR, 0.0–3.0] days, respectively (p < 0.001). In addition, monthly AMU days and tablets were also significantly decreased from median 28.0 [IQR, 20.0–30.0] days to 8.0 [IQR, 4.8–11.3] days, and 30.0 [IQR, 22.0–54.0] tablets to 9.5 [IQR, 4.8–13.5] tablets, respectively (p < 0.001). The good MHD and MMD responder rates were 75.0% and 85.7%, respectively. The rate of reducing AMU was 78.6%. HIT-6 and MSQ scores decreased significantly from baseline to after each CGRP-mAb injection (p < 0.001). Conclusions When CGRP-mAb was administered to MOH of migraine, the frequency of headache symptoms and AMU were reduced without abrupt drug discontinuation and no hospitalization.

show abstract

Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study

Cited by 4 publications

References 15 publications

Headache Education by E-Learning Through Social Networking Services (Social Media)

Headache Education by E-Learning Through Social Networking Services (Social Media)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study

Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization

Contact Info

Product

Resources

About